AR222, AR249, AS274, AS702 and AS708 antibodies recognize the spike S protein from SARS-CoV-2 by immunofluorescence

Anna Marchetti[1], Frederic Zenhausern[2,3,4]

[1] *Geneva Antibody Facility, Faculty of Medicine, University of Geneva, 1 rue Michel Servet, CH-1211, Geneva, Switzerland*
[2] *Center for Applied NanoBioscience and Medicine, The University of Arizona, Phoenix, AZ 85004, USA*
[3] *Whitespace Enterprise Corporation, 1305 Auto Drive, Tempe, AZ 85284, USA*
[4] *School of Pharmaceutical Sciences, University of Geneva, 1 rue Michel Servet, CH-1211, Geneva, Switzerland*

Abstract

The recombinant antibodies AR222, AR249, AS274, AS702 and AS708 detect by immunofluorescence the spike S protein from SARS-CoV-2.

Introduction

The spike (S) glycoprotein mediates attachment of coronaviruses to the host ACE2 receptor and fusion with the host cell membrane (Yan *et al.*, 2020). Five recombinant antibodies (AR222, AR249, AS274, AS702 and AS708) successfully detect by immunofluorescence the S protein from SARS-CoV-2 (UniProt P0DTC2) expressed in Vero-B4 cells.

Materials & Methods

Antibodies: ABCD_AQ806, ABCD_AR222, ABCD_AR249, ABCD_AS273, ABCD_AS274, ABCD_AS702 and ABCD_AS708 antibodies (ABCD nomenclature, https://web.expasy.org/abcd/) were produced by the Geneva Antibody Facility (http://www.unige.ch/medecine/antibodies/) as mini-antibodies with the antigen-binding portion fused to a mouse IgG2A Fc. The synthesized scFv sequences (GeneArt, Invitrogen) correspond to the sequences of the variable regions joined by a peptide linker $(GGGGS)_3$ (see Table 1 for clone names and references). HEK 293T suspension cells (growing in FreeStyle™ 293 Expression Medium, Gibco 12338) were transiently transfected with the vector coding for the scFv-Fc or VHH-Fc of each antibody. Supernatants (see Table 1 for individual yields) were collected after 4 days.

Table 1: Clone number, epitope, reference and production yields for the antibodies used in this study.

ABCD	Clone	Epitope	Reference	Yield (mg/L)
AQ806	VHH-72	S1/RBD	Wrapp et al., 2020	50
AR222	Sb#14	S1/RBD	Walter *et al.*, 2020	60
AR249	Sb#45	S1/RBD	Walter *et al.*, 2020	100
AS274	H4	S1/RBD	Wu *et al.*, 2020	20
AS702	CV24	S1	Seydoux *et al.*, 2020	20
AS708	CV30	S1/RBD	Seydoux *et al.*, 2020	20

Antigen: Vero-B4 adherent cells (growing in DMEM, Gibco 11960044, supplemented with 10% FBS), were transiently transfected 24 h before the experiment with a vector coding for the full-length SARS-CoV-2 S protein (BEI Resources, NR-52310, pCAGGS vector containing the full-length SARS-CoV-2/Wuhan-Hu-1 S glycoprotein coding sequence). Transfected cells were then seeded on multi-test glass slides (Thermo Fisher 15546375), and used to detect the viral protein. Non-transfected cells were used as a negative control.

Protocol: Transfected Vero-B4 cells were fixed with ice-cold Acetone/Methanol (ratio 1:1) for 10 min, and slides rehydrated for 10 min in PBS + 0.1% Tween20 (w/v) (PBS-T). Cells were then blocked in PBS-T + 0.2% BSA (w/v) for 30 min, and then incubated with the anti-S antibodies (final concentration 5 mg/L in PBS-T + BSA) for 1 h. After 3 washes with PBS-T, cells were incubated for 30 min in PBS-T + BSA with secondary goat anti-mouse IgG conjugated to AlexaFluor-488 (1:400, Molecular Probes, A11029). After 3 washes with PBS-T, slides were briefly rinsed with dH_2O, and mounted with Möwiol (Hoechst) + 2.5% (w/v) DABCO (Fluka 33480). Pictures were taken using a Zeiss LSM700 confocal microscope, with a 63x Neofluar oil immersion objective.

Results

AR222, AR249, AS274, AS702 and AS708 antibodies specifically detected a signal in Vero-B4 cells transfected with the SARS-CoV-2 S protein (Fig. 1); AQ806 was used as a positive control (Marchetti *et al.*, 2020). The distribution observed is consistent with a presence mostly in the early secretory pathway (endoplasmic reticulum and Golgi apparatus). The specificity of the signal was verified by the absence of staining in non-transfected cells (Fig. 1).



Fig. 1. Antibodies AQ806, AR222, AR249, AS274, AS702 and AS708 specifically labeled Vero-B4 cells expressing the SARS-CoV-2 S protein. No labeling was seen in non-transfected cells. Scale bar: 20 µm.

References

Marchetti A, Hammel P, Zenhausern F. AI334, AQ806 and RB596 antibodies recognize the spike S protein from SARS-CoV-2 by immunofluorescence. Antib. Rep. 2020, 3:e219. doi:10.24450/journals/abrep.2020.e219

Seydoux E, Homad LJ, MacCamy AJ, *et al*. Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity 2020; 53:1-8. PMID: 32561270.

Walter JD, Hutter CAJ, Zimmermann I, *et al*. Sybodies targeting the SARS-CoV-2 receptor-binding domain. Preprint. bioRxiv 2020; 2020.04.16.045419. doi:10.1101/2020.04.16.045419

Wrapp D, De Vlieger D, Corbett KS, *et al*. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell 2020; 181:1004-1015. PMID:32375025

Wu Y, Wang F, Shen C, *et al.* A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 2020; 368:1274-1278. PMID:32404477

Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367:1444-1448. PMID:32132184

Acknowledgments

This work was co-sponsored by NASA TRISH contract #NNX16AO69A/CAT0001. The following reagent was obtained through BEI Resources, NIAID, NIH: Vector pCAGGS containing the SARS-related Coronavirus 2, Wuhan-Hu-1 Spike glycoprotein gene, NR-52310.

Conflict of interest

The authors declare no conflict of interest.